Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.

doi:10.1200/JCO.2015.66.0001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2016

Chagtai Tasnim, Zill Christina, Dainese Linda, Wegert Jenny, Savola Suvi, Popov Sergey, Mifsud William, Vujanić Gordan, Sebire Neil, Le Bouc Yves, Ambros Peter F, Kager Leo, O'Sullivan Maureen J, Blaise Annick, Bergeron Christophe, Mengelbier Linda Holmquist, Gisselsson David, Kool Marcel, Tytgat Godelieve A M, van den Heuvel-Eibrink Marry M, Graf Norbert, van Tinteren Harm, Coulomb Aurore, Gessler Manfred, Williams Richard Dafydd, Pritchard-Jones Kathy

Abstract excerpt

PURPOSE: Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 1

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Neoadjuvant Therapy

Share to Nephrectomy

Share to Proportional Hazards Models

Share to Wilms Tumor

Source

Open in PubMed Open full text

Identifiers

PMID: 27432915
DOI: 10.1200/JCO.2015.66.0001
PMCID: PMC5505170

Genes

EFS
MYCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.PMID 27432915Read ↗

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.Semantic proximity Read ↗

The Clinical Impact of Somatic Copy Number Variations in Patients With Stage IV Wilms Tumor Enrolled in the SIOP 2001 Trial and StudySemantic proximity Read ↗

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533Semantic proximity Read ↗

Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.Semantic proximity Read ↗

The molecular biology of Wilms' tumourSemantic proximity Read ↗

The genetic factors contributing to the development of Wilm's tumor and their clinical utility in its diagnosis and prognosis.Semantic proximity Read ↗

Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.Semantic proximity Read ↗

Molecular characterization reveals subclasses of 1q gain in intermediate-risk Wilms tumorsSemantic proximity Read ↗

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.Semantic proximity Read ↗

Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.Semantic proximity Read ↗

The role of the Wilms tumour gene (<i>WT1</i>) in normal and malignant haematopoiesisSemantic proximity Read ↗

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.